Concurrent chemoradiotherapy with S‑1 in patients with stage III‑IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level

  • Authors:
    • Ryuji Murakami
    • Akiko Semba
    • Kenta Kawahara
    • Keiya Matsuyama
    • Akimitsu Hiraki
    • Masashi Nagata
    • Ryo Toya
    • Yasuyuki Yamashita
    • Natsuo Oya
    • Hideki Nakayama
  • View Affiliations

  • Published online on: May 29, 2017     https://doi.org/10.3892/mco.2017.1276
  • Pages: 140-144
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to retrospectively evaluate the treatment outcomes of concurrent chemoradiotherapy (CCRT) with S‑1, an oral fluoropyrimidine anticancer agent, for advanced oral squamous cell carcinoma (SCC). The study population consisted of 47 patients with clinical stage III or IV oral SCC, who underwent CCRT with S‑1. Pretreatment variables, including patient age, clinical stage, T classification, midline involvement of the primary tumor and nodal status, were analyzed as predictors of survival. In addition to the N classification (node‑positive, multiple and contralateral), the prognostic impact of the level of nodal involvement was assessed. Nodal involvement was mainly observed at levels Ib and II; involvement at levels Ia and III‑V was considered to be anterior and inferior extension, respectively, and was recorded as extensive nodal involvement (ENI). The 3‑year overall survival (OS) and progression‑free survival (PFS) rates were 37 and 27%, respectively. A finding of ENI was a significant factor for OS [hazard ratio (HR)=2.16; 95% confidence interval (CI): 1.03‑4.55; P=0.038] and PFS (HR=2.65; 95% CI: 1.32‑5.33; P=0.005); the 3‑year OS and PFS rates in patients with vs. those without ENI were 23 vs. 50% and 9 vs. 43%, respectively. The other variables were not significant. Therefore, CCRT with S‑1 may be an alternative treatment for advanced oral SCC; favorable outcomes are expected in patients without ENI.
View Figures
View References

Related Articles

Journal Cover

July 2017
Volume 7 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Murakami, R., Semba, A., Kawahara, K., Matsuyama, K., Hiraki, A., Nagata, M. ... Nakayama, H. (2017). Concurrent chemoradiotherapy with S‑1 in patients with stage III‑IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level. Molecular and Clinical Oncology, 7, 140-144. https://doi.org/10.3892/mco.2017.1276
MLA
Murakami, R., Semba, A., Kawahara, K., Matsuyama, K., Hiraki, A., Nagata, M., Toya, R., Yamashita, Y., Oya, N., Nakayama, H."Concurrent chemoradiotherapy with S‑1 in patients with stage III‑IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level". Molecular and Clinical Oncology 7.1 (2017): 140-144.
Chicago
Murakami, R., Semba, A., Kawahara, K., Matsuyama, K., Hiraki, A., Nagata, M., Toya, R., Yamashita, Y., Oya, N., Nakayama, H."Concurrent chemoradiotherapy with S‑1 in patients with stage III‑IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level". Molecular and Clinical Oncology 7, no. 1 (2017): 140-144. https://doi.org/10.3892/mco.2017.1276